Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer

Cancer Medicine

Volumn 1, Issue 2, 2012, Pages 218-229

  Horio, Maiko ^a   Kato, Takuya ^a   Mii, Shinji ^a   Enomoto, Atsushi ^a   Asai, Masato ^a   Asai, Naoya ^a   Murakumo, Yoshiki ^a   Shibata, Kiyosumi ^a   Kikkawa, Fumitaka ^a   Takahashi, Masahide ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Carboplatin; Chemoresistance; Epithelial ovarian cancer; Paclitaxel; RET finger protein

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; IRINOTECAN; PACLITAXEL; REGULATOR PROTEIN; RET FINGER PROTEIN; UNCLASSIFIED DRUG; VINBLASTINE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVARY CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR XENOGRAFT;

EID: 84895843559     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.32     Document Type: Article

References (32)

1. Jemal, A., R. Siegel, J. Xu, and E. Ward. 2010. Cancer statistics, 2010. CA Cancer J. Clin. 60:277-300.
2. Ushijima, K. 2009. Current status of gynecologic cancer in Japan. J. Gynecol. Oncol. 20:67-71.
3. Ferlay, J., H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127:2893-2917.
4. Engel, J., R. Eckel, G. Schubert-Fritschle, J. Kerr, W. Kuhn, J. Diebold, et al. 2002. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur. J. Cancer 38:2435-2445.
5. Averette, H. E., M. F. Janicek, and H. R. Menck. 1995. The National Cancer Data Base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 76:1096-1103.
6. Bookman, M. A. 2011. Update of randomized trials in first-line treatment. Ann. Oncol. 22:viii52-viii60.
7. Harries, M., andGore M. 2002. Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol. 3:537-545.
8. Muggia, F. M., P. S. Braly, M. F. Brady, G. Sutton, T. H. Niemann, S. L. Lentz, et al. 2000. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 18:106-115.
9. Reles, A., W. H. Wen, A. Schmider, C. Gee, I. B. Runnebaum, U. Kilian, et al. 2001. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin. Cancer Res. 7:2984-2997.
10. Hetland, T. E., E. Hellesylt, V. A. Florenes, C. Trope, B. Davidson, and J. Kaern. 2011. Class III beta-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hum. Pathol. 42:1019-1026.
11. Yan, X., J. Yin, H. Yao, N. Mao, Y. Yang, and L. Pan. 2010. Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer. Cancer Res. 70:1616-1624.
12. Kassim, S. K., H. S. Ali, M. M. Sallam, S. T. Fayed, L. S. Seada, E. abd-Elkawy, et al. 1999. Increased bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer. Clin. Biochem. 32:333-338.
13. Takahashi, M., J. Ritz, and G. M. Cooper. 1985. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42:581-588.
14. Takahashi, M., Y. Inaguma, H. Hiai, and F. Hirose. 1988. Developmentally regulated expression of a human "finger"-containing gene encoded by the 5′ half of the ret transforming gene. Mol. Cell. Biol. 8:1853-1856.
15. Takahashi, M., and G. M. Cooper. 1987. ret transforming gene encodes a fusion protein homologous to tyrosine kinases. Mol. Cell. Biol. 7:1378-1385.
16. Shimono, Y., H. Murakami, Y. Hasegawa, and M. Takahashi. 2000. RET finger protein is a transcriptional repressor and interacts with enhancer of polycomb that has dual transcriptional functions. J. Biol. Chem. 275:39411-39419.
17. Shimono, Y., H. Murakami, K. Kawai, P. A. Wade, K. Shimokata, and M. Takahashi. 2003. Mi-2 beta associates with BRG1 and RET finger protein at the distinct regions with transcriptional activating and repressing abilities. J. Biol. Chem. 278:51638-51645.
18. Krutzfeldt, M., M. Ellis, D. B. Weekes, J. J. Bull, M. Eilers, M. D. Vivanco, et al. 2005. Selective ablation of retinoblastoma protein function by the RET finger protein. Mol. Cell 18:213-224.
19. Kato, T., Y. Shimono, M. Hasegawa, M. Jijiwa, A. Enomoto, N. Asai, et al. 2009. Characterization of the HDAC1 complex that regulates the sensitivity of cancer cells to oxidative stress. Cancer Res. 69:3597-3604.
20. Tsukamoto, H., T. Kato, A. Enomoto, N. Nakamura, Y. Shimono, M. Jijiwa, et al. 2009. Expression of Ret finger protein correlates with outcomes in endometrial cancer. Cancer Sci. 100:1895-1901.
21. Markman, M., and M. A. Bookman. 2000. Second-line treatment of ovarian cancer. Oncologist 5:26-35.
22. Watanabe, R., H. Nakamura, H. Masutani, and J. Yodoi. 2010. Anti-oxidative, anti-cancer and anti-inflammatory actions by thioredoxin 1 and thioredoxin-binding protein-2. Pharmacol. Ther. 127:261-270.
23. Kaimul, A. M., H. Nakamura, H. Masutani, and J. Yodoi. 2007. Thioredoxin and thioredoxin-binding protein-2 in cancer and metabolic syndrome. Free Radic. Biol. Med. 43:861-868.
24. 3 up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J. Biol. Chem. 274:21645-21650.
25. 3-up-regulated protein-1 is a stress-responsive gene that regulates cardiomyocyte viability through interaction with thioredoxin. J. Biol. Chem. 277:26496-26500.
26. Junn, E., S. H. Han, J. Y. Im, Y. Yang, E. W. Cho, H. D. Um, et al. 2000. Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J. Immunol. 164:6287-6295.
27. Chu, Y., and X. Yang. 2011. SUMO E3 ligase activity of TRIM proteins. Oncogene 30:1108-1116.
28. Murray, S., E. Briasoulis, H. Linardou, D. Bafaloukos, and C. Papadimitriou. 2012. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat. Rev. 38:890-903.
29. Wahl, A. F., K. L. Donaldson, C. Fairchild, F. Y. Lee, S. A. Foster, G. W. Demers, et al. 1996. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med. 2:72-79.
30. Catuogno, S., L. Cerchia, G. Romano, P. Pognonec, G. Condorelli, and V. de Franciscis. 2012. miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene [Epub ahead of print]. doi: 10.1038/onc.2012.51.
31. Rerole, A. L., J. Gobbo, A. De Thonel, E. Schmitt, J. P. Pais de Barros, A. Hammann, et al. 2011. Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. Cancer Res. 71:484-495.
32. Olsen, L. S., P. J. Hjarnaa, S. Latini, P. K. Holm, R. Larsson, E. Bramm, et al. 2004. Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of IKK activity. Int. J. Cancer 111:198-205.